Consistent with our results, PLOD2 overexpression has been reported to be associated with the clinical progression and poor outcome of patients with bladder cancer, hepatocellular carcinoma or glioblastoma [14, 15]. This evidence concerns the gene PLOD2 and hepatocellular carcinoma.